Efficacy of mipragoside ophthalmic gel in vernal keratoconjunctivitis.
To evaluate the efficacy of Mipragoside, a ganglioside derivative, in vernal keratoconjunctivitis we performed a controlled randomised clinical trial involving 24 patients (mean age 10 +/- 3.4 years, range 5-20 years). Patients received either Mipragoside 0.5% aqueous ophthalmic gel or placebo four times a day for 2 weeks after a week of treatment with placebo. Ocular signs and symptoms were evaluated and considered for statistical analysis. Results show that Mipragoside significantly reduces all symptoms, being most effective on itching (p = 0.01; p = 0.0001) and hyperaemia (p = 0.01; p = 0.0006) after 1 and 2 weeks respectively when compared with placebo. Physician judgement of drug efficacy at the end of treatment was significantly in favour of Mipragoside (p = 0.0001) compared with placebo. We conclude that Mipragoside topical treatment improves symptoms of patients with vernal keratoconjunctivitis and we postulate a possible anti-inflammatory activity of this compound.
Centofanti
M
M
Department of Ophthalmology, University of Rome 'Tor Vergata', Italy.
Schiavone
M
M
Lambiase
A
A
Taffara
M
M
Giuffrida
S
S
Bonini
S
S
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D003233:Conjunctivitis, Allergic / Q000188:drug therapy*; D005260:Female; D005677:G(M1) Ganglioside / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005782:Gels; D006801:Humans; D008297:Male; D016896:Treatment Outcome
D005782:Gels; D005677:G(M1) Ganglioside; C079117:mipragoside